Vectura Share Discussion Threads

[justiceforthemany] 25/6/2020 15:11

The share price movements here are highly volatile and make no sense at all - smacks of manipulation.

[pooroldboy55] 25/6/2020 15:09

As i said a few days ago pump and dump it was plainly obvious after the million plus trade what was going on as we have no positive news to push price up .What can we expect from management nothing as normal.i stay here as for me its a small holding 30000 and i'm very lucky i don't need the money and like to see whats going on but as an investment no way.
Ps
always news tomorrow but tomorrow with VEC never seems to come

[a1ord53] 25/6/2020 14:45

Dump again ? shorts pumped again and dumped
Without real material news this stock can go only down - buy back attracting short sellers - damned company and greedy management - again the same - very disappointing :(
Imo 10mil to pay divi would be much better than buy back !
Also market makers are very manipulative !

[vecturaking] 25/6/2020 07:25

in my view we have 130 Pence for the short term here on the cards
with imminent news Breaking on various points
vectura maintaining the second quarter forecasts
great portfolio of products and favourable news stream

i believe that they are best suited to Announce Major JV Deals

i note that this may effect there buyback program
but being transparent is of Great importance

good luck all

[diesel] 24/6/2020 23:29

I presume that we will need the share price to rise as shares are bought back and cancelled, if so what would the share price need to be in Sept too qualify for fate 250 status, everything else being static.

[boadicea] 24/6/2020 22:04

As things currently stand, VEC would be in the FTSE250 if reviewed now. However I assume that, as 2nd reserve candidate (behind CMC Markets), it only requires two suspensions or expulsions (e.g. merger, takeover, administration) in the top 350 companies for VEC to be called up. Given present conditions this seems more than likely.

[a1ord53] 24/6/2020 16:53

Copied from above site :


Summary
Wednesday June 24, 2020 at 11am EDT |8am PDT |4pm BST |5pm CEST
Event Overview:
Dry powder inhalers are an important technology for the delivery of therapies for both respiratory and non-respiratory disease areas. The development of such drug-device combination products is highly complex and several factors can have a significant impact on the success of the program. This webcast discusses the key considerations to reduce risk when developing a DPI product from early clinical trials through to scale-up, and provides insights for both novel and generic development programs.

Key Learning Objectives:
Understanding different options for dry powder inhaler technology
Key considerations for DPI product development
Manufacturing strategies for seamless transition and scalability from lab to commercial scale
Relevant regulatory guidance and risk-based approaches to process development and device design
Device strategies for novel and generic inhaled development programs
Who Should Attend:
Pharmaceutical and biotech companies developing inhaled medicines (new chemical entities and/or generics)
Manager/Director/Senior Director/Vice President/SVP, R&D
Manager/Director/Senior Director/Vice-President/SVP, Product Development
Manager/Director/Senior Director/Vice President/SVP, Procurement and Sourcing
Manager/Director/Senior Director/Vice President/SVP, Inhaled Device Development

For questions please reach out to Martha Devia: [e-mail]
Speakers
Andreas Meliniotis
Andreas Meliniotis
Director, Device Development
Vectura Group plc.
Andreas Meliniotis is Director of Device Development at Vectura and leads the engineering and device development group based in Cambridge, UK. With over 15 years’ experience at Vectura, Andreas has led the design and development of several multi-dose dry powder inhalers as well as nebulizers and connected device technology.

Prior to joining Vectura, Andreas worked for the Cambridge Design Partnership and The Technology Partnership developing glucose measurement devices and industrial printing technology respectively.

Andreas is a Chartered Mechanical Engineer and Chartered Manager and holds a bachelor’s degree in mechanical engineering from the University of Nottingham, UK.

[a1ord53] 24/6/2020 16:16

Anybody registered for this Vectura Webcast ? Any idea what is this ?


event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&partnerref=MJHSOCIAL&eventid=2358871&sessionid=1&key=C755948E5F700F731D443BB8770B2169&regTag=&sourcepage=register

[rolo7] 24/6/2020 12:45

On a big market cap like this that would take some doing?

[rolo7] 24/6/2020 12:44

Plus fste 250 entry in September at current market cap?!

[dukew1] 23/6/2020 13:53

An inhalable version of a C19 treatment is currently being trialled alongside the injectable cobra study. I can't envisage any of Vecturas devices being able to be provided in near enough units though. Even the pMDIs are done by contract.

[vecturaking] 23/6/2020 13:34

ReRating in Vectura on the cardsToday

Vectura is the leader in inhaled products

Due to the covid Situation this has Opened up Numerous opportunities with major players to be announced shortly in my view

Make no mistake we are going a lot Higher due to a ReRating

Enjoy the lovely weather

[vecturaking] 23/6/2020 04:32

I think big News coming here

Register for our LIVE webcast with @VecturaGroup "Dry Powder Inhalers: Key Considerations for Combination Product Development" on Wednesday June 24, 2020 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST
ow.ly/ChwU50AcREx

[fhmktg] 22/6/2020 23:37

I have emailed to ask ....probably won't disclose on confidentiality grounds!

[fhmktg] 22/6/2020 23:32

Injection at the moment, but trials of an inhaled version start in August....would be a great tick for VER if they provide one of their devices!

[justiceforthemany] 22/6/2020 18:02

UT shaved a penny off at the close.
Buy back has slowed in recent days.

[pooroldboy55] 22/6/2020 16:29

Question are we seeing yet again a pump and dump re that large late trade on friday.

[best1467] 20/6/2020 06:21

Last comment Frontier IP is the listed company that Takes the early stakes in the start-ups and helps with the issues you mention Pulsiv IV is one of many they have .
Will not mention again( Back to Vectura)

[best1467] 20/6/2020 06:15

Polaris

Would agree reference start-ups the only thing to add is have a look at Frontier IP the particular company I mentioned as been granted several worldwide patents and recently done a collaboration with Bosch and we all know the incredible growth market with Battery power In my opinion this one stake alone could create many multiples of the current valuation

[polaris] 19/6/2020 22:59

Well, those numbers today are pretty stark in terms of where the Covid-19 pandemic is going. The US are slowly losing control in their southern states and may see new case highs on a countrywide scale next week if they are not careful. Arizona, Florida, Texas and the Carolinas are not looking good and California continues to rise slowly but surely. The GDP of California alone is up there in the world scale of things. The situation in Mexico cannot be helping, with the trade across the border.

I think it might just get ugly again for the stock markets, particularly US where valuations remain extended, they are assuming a full economic recovery within 3-6 months. The official figures are around 120 k deaths in the US but the total excess deaths are now around 170 k.

South America is becoming a nightmare scenario. Everyone in Europe is assuming that we have seen the back of the worst but the recent outbreak in Beijing shows that the only way to approach this IS the Chinese way. Shut it down completely and test everyone concerned. Send in the military. Sooner or later something is going to give in the markets and i can't see it being to the upside.

That said, i hit my latest trading target for the DOW short position around the close of business and so only short TSLA in the US arena right now. That is still underwater, as the bubble continues to expand. By the time of the Q2 numbers for TSLA, i expect a very different outlook...and stock price.

[polaris] 19/6/2020 19:38

That is VERY hit and miss. I have a few colleagues with start-ups, the majority fail after 1-3 years. If nothing else, the average scientist knows nothing about how to run a business. Most also do not adequately protect the IP and can be squeezed out, even if they have a good idea. We are not really brought up with the patent/protecting IP mantra. For me, I am only interested in the science...not ideal for a successful company.

[best1467] 19/6/2020 19:06

Polaris
Thought I would mention this company related to FIPP which takes small positions in start up university technology .
you May well be aware the company is Pulsiv IV which Fipp which is the ticker as a substantial stake along with a number of other cutting edge technology start ups.
I came extremely close to selling 50% of my Vectura holding yesterday but didn’t in the end having seen the constant trading range finally broken we should if following the normal pattern See a further quick spike into the £1.20 range but been wrong calling this share many times before But today’s action gives me confidence because in the past we’ve always soon a instant retrace